Earticle

초록

영어

Alendronate is a bisphosphonate that selectively inhibits osteoclast-mediated bone resorption. Dosing convenience is animportant element for the enhancement of patient compliance and the effective management of osteoporosis. The pur-pose of this study was to compare the effectiveness and compliance among alendronate pharmaceutical products(oralonce-weekly alendronate 70mg, daily alendronate 10mg, and once-weekly alendronate 70mg with Vitamin D3 2800IU) in terms of the change in bone mineral density (BMD), biochemical markers, and compliance estimates. A retro-spective chart review was conducted in patients with osteoporosis who received alendronate 70mg (Group 1), alendr-onate 10 mg (Group 2), or alendronate 70mg with Vitamin D3 2800 IU (Group 3) at the endocrinology department ofa hospital in Korea from Jan. 1, 1998 to Mar. 31, 2008. The primary endpoints were the increases in spine antero-pos-terior BMD T-score and femur trochanter BMD T-score, and the compliance of alendronate products. Secondary end-points included changes in bone turnover-related biochemical markers including bone-specific alkaline phosphatase,urinary N-terminal telopeptides (NTX) and osteocalcin, and in serum vitamin D3 concentration. There was no statisticaldifference in the BMD increase among the three alendronate products; spine BMD T-score increased by 0.49±0.52,0.39±0.48 and 0.50±0.41, and femur trochanter BMD T-score by 0.29±0.42, 0.21±0.53 and 0.24±0.22 in Group 1, 2 and3, respectively. With respect to the increases in femur trochanter BMD T-score and the decreases in NTX and osteocal-cin, 70mg once-weekly group was remarkably superior to 10mg daily group (p<0.05) The compliance of 70mgonce-weekly group was significantly higher than that of 10mg daily treatment group (p<0.001). In conclusion, allthree alendronate treatment groups were equivalent in effectiveness, and the compliance of 70 mg once-weekly groupwas better than that of 10 mg daily treatment group.

목차

abstract
 연구 방법
 연구결과
 고찰 및 결론
 참고문헌

키워드

저자

• 윤지원 [ Jiwon Yoon | 이화여자대학교 임상보건과학대학원(Graduate School of Clinical Health Sciences, Ewha Womans University) ]
• 이병구 [ Byungkoo Lee | 이화여자대학교 생명약학부(Division of Life and Pharmaceutical Sciences, Ewha Womans University) ]
• 송영천 [ Youngchun Song | 서울아산병원(Division of Pharmaceutical Services, Seoul Asan Medical Center) ]
• 김재연 [ Jaeyoun Kim | 서울아산병원(Division of Pharmaceutical Services, Seoul Asan Medical Center) ]
• 신혜영 [ Hyeyoung Shin | 서울아산병원(Division of Pharmaceutical Services, Seoul Asan Medical Center) ]
• 이연홍 [ Yeonhong Lee | 이화여자대학교 생명약학부(Division of Life and Pharmaceutical Sciences, Ewha Womans University) ]
• 곽혜선 [ Hyesun Gwak | 이화여자대학교 생명약학부(Division of Life and Pharmaceutical Sciences, Ewha Womans University) ]

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국임상약학회지 [Korean Journal of Clinical Pharmacy]

• 간기

  계간

• pISSN

  1226-6051

• 수록기간

  1991~2026

• 등재여부

  KCI 등재

• 십진분류

  KDC 518 DDC 615